Source-grounded facts extracted from CUMBERLAND PHARMACEUTICALS INC's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
James L. Herman departed as Vice President Trade & Distribution and Corporate Compliance Officer at CUMBERLAND PHARMACEUTICALS INC.
“Effective July 31, 2026, in connection with the closing of the Transaction, Chris T. Bitterman, Vice President Sales & Marketing, and James L. Herman, Vice President Trade & Distribution and Corporate Compliance Officer, will resign from the Company and will be hired by an affiliate of Apotex.”
Chris T. Bitterman departed as Vice President Sales & Marketing at CUMBERLAND PHARMACEUTICALS INC.
“Effective July 31, 2026, in connection with the closing of the Transaction, Chris T. Bitterman, Vice President Sales & Marketing, and James L. Herman, Vice President Trade & Distribution and Corporate Compliance Officer, will resign from the Company and will be hired by an affiliate of Apotex.”
CUMBERLAND PHARMACEUTICALS INC reported three months ended March 31, 2026 results: revenue $9.1 million, net income net loss for the first quarter of 2026 was approximately $3.3 million, EPS $0.13 per share.
“Pharmaceuticals Inc. (Nasdaq: CPIX) , a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined net revenues of $9.1 million during the first quarter of 2026. Cumberland ended the quarter with $71.0 million in total assets, $49.7 million in liabilities and $21.6 million of shareholders’ equity. “We”
CUMBERLAND PHARMACEUTICALS INC entered into Asset Purchase Agreement with Apotex Inc. valued at $100,000,000 (effective 2026-04-22).
“On April 22, 2026, Cumberland Pharmaceuticals Inc. (the “ Company ” or “ Cumberland ”) entered into a strategic transaction (the “ Transaction ”) to integrate its commercial products with the U.S. branded business of an affiliate of Apotex Inc., a corporation incorporated under the laws of the Province of Ontario (“ Apotex ”), in exchange for $100,000,000 payable at the closing of the Transaction.”
CUMBERLAND PHARMACEUTICALS INC amended First Amendment to Amended and Restated Revolving Credit Note and Second Amendment to Amended and Restated Revolving Credit Loan Agreement with Pinnacle Bank valued at $15 million (effective 2025-11-18).
“On November 18, 2025, Cumberland Pharmaceuticals Inc. (the “Company” or “Cumberland”) and Pinnacle Bank ("Pinnacle") fully executed the First Amendment to Amended and Restated Revolving Credit Note and Second Amendment to Amended and Restated Revolving Credit Loan Agreement”
CUMBERLAND PHARMACEUTICALS INC incurred revolving credit of up to $15 million with Pinnacle Bank at Benchmark Term SOFR plus 2.75% maturing October 1, 2027.
“The Amendment provides for a principal available for borrowing of up to $15 million.”
CUMBERLAND PHARMACEUTICALS INC reported the three months ended March 31, 2024 results: revenue $8.5 million.
“Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, today announced that its product portfolio of FDA-approved brands delivered combined revenues of $8.5 million during the first quarter of 2024. The company ended the quarter with $82 million in total assets, $54 million in total liabilities and $27 million of shareholders’ equity. “It”
CUMBERLAND PHARMACEUTICALS INC shareholders approved Ratification of appointment of Carr, Riggs & Ingram, LLC as independent registered public accounting firm for year ending December 31, 2024 at the 2024-04-23 meeting.
“Appointment of Carr, Riggs & Ingram LLC as our independent registered public accounting firm for the year ending December 31, 2024 11,189,440 15,502 — 28,560 99.9%”
CUMBERLAND PHARMACEUTICALS INC shareholders approved Election of two Class II Directors at the 2024-04-23 meeting.
“For Against Withheld Abstentions % of Votes in Favor Martin S. Brown, Jr. 8,544,756 — 352,239 — 96.0% James R. Jones 8,411,468 — 485,527 — 94.5%”
CUMBERLAND PHARMACEUTICALS INC reported financial results for the year ended December 31, 2023.
“On March 5, 2024, Cumberland Pharmaceuticals Inc. (the "Company") issued a press release which provided a company update and the financial results for the three months and year ended December 31, 2023.”
CUMBERLAND PHARMACEUTICALS INC reported financial results for the three and nine months ended September 30, 2023.
“On November 7, 2023, Cumberland Pharmaceuticals Inc. (the "Company") issued a press release which provided a company update and the financial results for the three and nine months ended September 30, 2023.”
CUMBERLAND PHARMACEUTICALS INC incurred revolving credit of up to $25 million with Pinnacle Bank at Term SOFR plus a spread of 2.75% maturing October 1, 2026.
“a new Revolving Credit Loan Agreement with Pinnacle Bank (the “New Pinnacle Agreement”). The New Pinnacle Agreement provides for an aggregate principal funding amount of up to $25 million. It provides an initial revolving line of credit of up to $20 million with the ability for Cumberland to increase the amount to $25 million, under certain conditions. The New”
CUMBERLAND PHARMACEUTICALS INC terminated Prior Pinnacle Agreement with Pinnacle Bank valued at $5.1 million (effective 2023-09-05).
“Effective upon the execution of the New Pinnacle Agreement described in Item 1.01 above, the prior Revolving Credit Loan Agreement, as amended, originally dated July 28, 2017, by and between the Company and Pinnacle Bank (the "Prior Pinnacle Agreement") was terminated.”
CUMBERLAND PHARMACEUTICALS INC entered into New Pinnacle Agreement with Pinnacle Bank valued at $25 million (effective 2023-09-05).
“On September 5, 2023, Cumberland Pharmaceuticals Inc. (the "Company" or "Cumberland") entered into a new Revolving Credit Loan Agreement with Pinnacle Bank (the "New Pinnacle Agreement").”
CUMBERLAND PHARMACEUTICALS INC reported the first quarter of 2023 results: revenue $9.2 million, net income $0.2 million or $0.01 a share, EPS $0.01 a share.
“Cumberland Pharmaceuticals Reports First Quarter 2023 Financial Results & Company Update NASHVILLE, TENNESSEE (Tuesday, May 9, 2023) - Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) , a specialty pharmaceutical company, today announced that the Company’s product portfolio of FDA-approved brands delivered combined revenues of $9.2 million during the first quarter of 2023. Net income for the period was $0.2 million, or $0.01 a share, resulting in adjusted earnings of $1.7 million, or $0.11 a share.”
CUMBERLAND PHARMACEUTICALS INC shareholders approved Approval of an amendment to the Amended and Restated 2007 Long-Term Incentive Compensation Plan at the 2023-04-25 meeting.
“Approve an amendment to the amended and restated 2007 long-term incentive compensation plan 6,869,796 2,286,706 — 26,353 75.0%”
CUMBERLAND PHARMACEUTICALS INC shareholders approved Resolution regarding compensation of the named executive officers at the 2023-04-25 meeting.
“Resolution regarding compensation of named officers 8,228,888 926,046 — 27,921 89.9%”
CUMBERLAND PHARMACEUTICALS INC shareholders approved Ratification of the appointment of FORVIS, LLP as independent registered public accounting firm for the year ending December 31, 2023 at the 2023-04-25 meeting.
“Appointment of FORVIS, LLP as our independent registered public accounting firm for the year ending December 31, 2023 11,474,731 107,830 — 17,830 99.1%”
CUMBERLAND PHARMACEUTICALS INC shareholders approved Election of Directors at the 2023-04-25 meeting.
“The voting results were as follows: For Against Withheld Abstentions % of Votes in Favor Kenneth J. Krogulski 9,100,390 — 82,465 — 99.1% Caroline R. Young 8,326,006 — 856,849 — 90.7% Martin S. Brown, Jr. 9,053,642 — 129,213 — 98.6%”
CUMBERLAND PHARMACEUTICALS INC reported full year 2022 results: revenue Net revenues were $42.0 million, net income Net loss for the fourth quarter of 2022 was $2.4 million, and $5.6 million, or $0.38 per share, for the year., EPS $0.38 per share.
“(NASDAQ: CPIX) , a specialty pharmaceutical company today announced full year 2022 financial results and provided a Company update. Net revenues grew 17% over the prior year to $42 million, resulting in $8 million in cash flow from operations. As of December 31, 2022, the Company's total assets were $93 million, including $20 million in cash. Total liabilities were”
Joey A. Jacobs departed as Member of the Board of Directors at CUMBERLAND PHARMACEUTICALS INC.
“On January 14, 2023, Cumberland Pharmaceuticals Inc. ("Cumberland" or the "Company") learned that Joey A. Jacobs, a member of Cumberland’s Board of Directors, had passed away.”
CUMBERLAND PHARMACEUTICALS INC reported the nine months ended September 30, 2022 results: revenue $33 million.
“of 2022, included $4.0 million for Sancuso ® , $3.9 million for Kristalose ® , $1.9 million for Vibativ ® and $0.9 million for Caldolor ® . Year-to-date 2022 net revenues were $33 million, a 19% increase compared to $28 million for the first nine months of 2021. Year-to-date net revenues by product were $11.4 million for Kristalose, $10.8 million for Sancuso, $6.0”
CUMBERLAND PHARMACEUTICALS INC reported the three months ended September 30, 2022 results: revenue $11.4 million, net income Net loss for the third quarter of 2022 was $0.4 million.
“Pharmaceuticals Inc. (NASDAQ: CPIX) , a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined revenues of $11.4 million during the third quarter of 2022 - a 41% increase over the prior year period. Cumberland also reported a 19% increase in net revenues for the first nine months of the year”
Martin S. Brown Jr. was appointed as Director at CUMBERLAND PHARMACEUTICALS INC.
“Effective July 15, 2022, Cumberland Pharmaceuticals Inc. (the "Company") appointed Martin S. Brown Jr, an attorney with Adams & Reese LLP, as the newest member of its Board of Directors.”
Leo Pavliv retired as Executive Vice President, Chief Development & Operations Officer at CUMBERLAND PHARMACEUTICALS INC.
“On May 31, 2022, Cumberland Pharmaceuticals Inc. ("Cumberland" or the "Company") announced the retirement of Leo Pavliv, Cumberland’s Executive Vice President, Chief Development & Operations Officer.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.